Therapeutic Use of Stem Cells for Myocardial Infarction

Madigan, Mariah; Atoui, Rony

doi:10.3390/bioengineering5020028

Cited by 62 publications

(52 citation statements)

References 108 publications

(157 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Therefore, stem cell therapy has emerged as a new treatment method. 67 However, despite the great development of this therapy, the delivery of targeted stem cells and the tracking or detection of their proliferation still need efforts to optimize. In order to overcome these shortcomings, new methods are needed to achieve high concentration cells in damaged tissues and to monitor their proliferation and survival.…”

Section: Nps Application In the Treatment Of Amimentioning

confidence: 99%

Nanotechnology, an alternative with promising prospects and advantages for the treatment of cardiovascular diseases

Li¹,

Liang²,

Xiao³

et al. 2018

IJN

View full text Add to dashboard Cite

Cardiovascular diseases (CVDs) are one of the most important causes of mortality and affecting the health status of patients. At the same time, CVDs cause a huge health and economic burden to the whole world. Although a variety of therapeutic drugs and measures have been produced to delay the progress of the disease and improve the quality of life of patients, most of the traditional therapeutic strategies can only cure the symptoms and cannot repair or regenerate the damaged ischemic myocardium. In addition, they may bring some unpleasant side effects. Therefore, it is vital to find and explore new technologies and drugs to solve the shortcomings of conventional treatments. Nanotechnology is a new way of using and manipulating the matter at the molecular scale, whose functional organization is measured in nanometers. Because nanoscale phenomena play an important role in cell signal transduction, enzyme action and cell cycle, nanotechnology is closely related to medical research. The application of nanotechnology in the field of medicine provides an alternative and novel direction for the treatment of CVDs, and shows excellent performance in the field of targeted drug therapy and the development of biomaterials. This review will briefly introduce the latest applications of nanotechnology in the diagnosis and treatment of common CVDs.

show abstract

Section: Nps Application In the Treatment Of Amimentioning

confidence: 99%

Nanotechnology, an alternative with promising prospects and advantages for the treatment of cardiovascular diseases

Li¹,

Liang²,

Xiao³

et al. 2018

IJN

View full text Add to dashboard Cite

show abstract

“…Traditional clinical approaches for myocardial infarction rely on surgical revascularization procedures, such as coronary stenting or coronary artery bypass grafts (CABG). Although the novel therapeutics using cells (especially stem cells) ( Gao et al, 2013 ; Madigan and Atoui, 2018 ; Terashvili and Bosnjak, 2019 ), genes ( Oggu et al, 2017 ), exosomes ( Davidson and Yellon, 2018 ), and growth factors ( Crafts et al, 2015 ; Reboucas et al, 2016 ) are emerging and have shown significant research outcomes, numerous challenges still exist in translating those technologies into clinical practice ( Egwim et al, 2017 ).…”

Section: Introductionmentioning

confidence: 99%

Nanoparticle-Mediated Drug Delivery for Treatment of Ischemic Heart Disease

Fan

Joshi

et al. 2020

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

The regenerative capacity of an adult cardiac tissue is insufficient to repair the massive loss of heart tissue, particularly cardiomyocytes (CMs), following ischemia or other catastrophic myocardial injuries. The delivery methods of therapeutics agents, such as small molecules, growth factors, exosomes, cells, and engineered tissues have significantly advanced in medical science. Furthermore, with the controlled release characteristics, nanoparticle (NP) systems carrying drugs are promising in enhancing the cardioprotective potential of drugs in patients with cardiac ischemic events. NPs can provide sustained exposure precisely to the infarcted heart via direct intramyocardial injection or intravenous injection with active targets. In this review, we present the recent advances and challenges of different types of NPs loaded with agents for the repair of myocardial infarcted heart tissue.

show abstract

“…Стволовые/прогениторные клетки, рассматриваемые как альтернативный способ терапии сердечной недостаточности, способствуют регенерации поврежденного миокарда при инфаркте миокарда (ИМ) [15,19]. Показано, что аутологичные костномозговые мононуклеары при ишемии миокарда способствуют улучшению сократительной функции левого желудочка сердца, как следствие ангиогенеза в миокарде, опосредованного эндотелиальными прогениторными клетками (ЭПК) костного мозга [16,18].…”

Section: Introductionunclassified

Effect of erythropoietin on bone marrow mononuclear cells

et al. 2020

View full text Add to dashboard Cite

Stem/progenitor cells are considered an alternative method of heart failure therapy by promoting regeneration of damaged myocardium in myocardial infarction. Effectiveness of cell therapy depends on the population composition and functional activity of the cell graft, and, in turn, it depends on the conditions of microenvironment. Cultivation of stem/progenitor cells with erythropoietin stimulates proliferative potential causing in vitro resistance to hypoxia, and in vivo stimulation of angiogenesis. We aimed for assessing effects of erythropoietin upon hematopoietic cells. We studied some effects of short-term incubation of bone marrow mononuclear cells (BM-MNCs) in patients with coronary heart disease (CHD) with erythropoietin upon cellular phenotype, cell cycle, apoptosis and their proliferative potential. BM-MNCs were isolated from bone marrow aspirate from patients with CHD in a density gradient, then incubated for 60 minutes with erythropoietin (33.4 IU/ml). Using flow cytometric assay of the total BM-MNCs pool, we have shown there endothelial progenitor cells at different stages of maturation and differentiation, mesenchymal stem cells are. Their total number did not exceed 30%. Short-term incubation of BM-MNCs with erythropoietin reduces expression of CD184 “homing receptor” molecules on CD34+ cells, and causes increase of CD184 on CD31+ cells in the BM-MNCs pool (p < 0.05). In addition, erythropoietin has been shown to cause a delay of CD34+ cells in the resting phase (G0G1), reduce a proportion of cells in the synthetic phase (S) and mitosis (G2/M) (p<0.05), and does not affect apoptosis, as shown by Annexin V-FITC Apoptosis Detection Kit. Erythropoietin had no significant effects on expression on BM-MNCs surface molecules involved in providing adhesion, such as CD18, CD29, CD44, CD49a, CD54, CD62E, CD146, and CD202b. MTT-method has shown that the short-term preincubation of BM-MNCs with erythropoietin contributed to a significant decrease in proliferative activity of BM-MNCs (p < 0.05). However, there was a tendency towards increased resistance of erythropoietin-pretreated BM-MNCs to oxidative stress induced by hydrogen peroxide. We have also revealed a correlation between the numbers of endothelial progenitor cells at different stages of differentiation, and numbers of hematopoietic stem cells in the total BM-MNCs pool. The number of CD34+/CD133+, CD34- / CD31+, CD45+/EpoR+, and CD34+/EpoR+ in BM-MNCs pool are dependent on the age of patients. Hence, a short-term incubation of BM-MNCs with erythropoietin promotes the cells to be retained in resting phase of the cell cycle, thus, in turn, helping to reduce proliferative potential of BM-MNCs.

show abstract

Therapeutic Use of Stem Cells for Myocardial Infarction

Cited by 62 publications

References 108 publications

Nanotechnology, an alternative with promising prospects and advantages for the treatment of cardiovascular diseases

Nanotechnology, an alternative with promising prospects and advantages for the treatment of cardiovascular diseases

Nanoparticle-Mediated Drug Delivery for Treatment of Ischemic Heart Disease

Effect of erythropoietin on bone marrow mononuclear cells

Contact Info

Product

Resources

About